View source for Unfractionated heparin (UFH)

==General information==
Class/mechanism: Acts at multiple points in the coagulation cascade to inhibit clotting and the formation of fibrin clots.  Heparin interacts with antithrombin III (AT-III), inactivates the conversion of prothrombin to thrombin, inactivates thrombin and its effect of catalyzing the formation of fibrin from fibrinogen, and inhibits the activation of fibrin-stabilizing factor.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=665 Heparin package insert]</ref><ref>[[Media:Heparin.pdf | Heparin package insert (locally hosted backup)]]</ref><ref>[https://www.pfizerinjectables.com/products/Heparin_Sodium_Injection Heparin manufacturer's website]</ref>
<br>Route: IV, SC
<br>Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>

==Patient drug information==
*Brief patient counseling information can be found in the [http://labeling.pfizer.com/ShowLabeling.aspx?id=665 Heparin package insert]<ref name="insert"></ref>
*[http://www.uptodate.com/contents/heparin-patient-drug-information Heparin patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/heparin-patient-drug-information Heparin patient drug information (UpToDate)]</ref>

==References==
<references/>

[[Category:Drug index]]
[[Category:Anticoagulants]]
[[Category:Heparins]]

[[Category:Hematology medications]]

[[Category:Drugs FDA approved in 1939]]